
Ask a doctor about a prescription for VORICONAZOL SALA 200 mg POWDER FOR SOLUTION FOR INFUSION
Package Leaflet: Information for the Patient
Voriconazole Sala 200 mg Powder for Solution for Infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Keep this leaflet, you may need to read it again.
If you have any further questions, ask your doctor, pharmacist, or nurse.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the Package Leaflet
This medication contains the active ingredient voriconazole. Voriconazole is an antifungal medication. It works by eliminating or preventing the growth of fungi that cause infections.
It is used for the treatment of patients (adults and children 2 years of age or older) with:
severe invasive infections caused by Candida sp, when the fungus is resistant to fluconazole (another antifungal medication),
This medication is used in patients with severe fungal infections that can be life-threatening.
Prevention of fungal infections in bone marrow transplant recipients with high risk.
This medication should only be used under medical supervision.
Do not usethis medication:
It is very important that you inform your doctor or pharmacist if you are using or have recently used other medications, including those purchased without a prescription, or herbal remedies.
During treatment with voriconazole, you should not take the following medications:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to use this medication if:
You should avoid any exposure to the sun and sunlight during treatment. It is essential that you cover exposed areas and use a sunscreen with a high sun protection factor (SPF), as your skin may be more sensitive to the sun's UV rays. This sensitivity may be increased further by the use of other medications that make your skin more sensitive to sunlight, such as methotrexate. These precautions also apply to children.
While you are being treated with this medication, inform your doctor if you experience:
If you develop skin disorders such as those described above, your doctor may refer you to a dermatologist, who may consider it essential to examine you regularly after the consultation. There is a small probability that you may develop skin cancer with long-term use of this medication.
If you develop signs of "adrenal insufficiency" in which the adrenal glands do not produce sufficient amounts of certain steroid hormones, such as cortisol, which can cause symptoms such as: chronic or prolonged fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, inform your doctor.
If you present signs of "Cushing's syndrome" in which the body produces too much cortisol hormone, which can cause symptoms such as: weight gain, hump of fat between the shoulders, rounded face, darkening of the skin of the abdomen, thighs, breasts, and arms, thin skin, easy bruising, high blood sugar levels, excessive hair growth or excessive sweating, inform your doctor.
Your doctor should monitor your liver and kidney function through blood tests.
Children and adolescents.
This medication should not be administered to children under 2 years of age.
Use ofvoriconazole with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may take any other medications.
Some medications, when used at the same time as voriconazole, can affect the action of this medication or voriconazole may affect the action of other medications.
Inform your doctor if you are using the following medications, as concurrent treatment with voriconazole should be avoided if possible:
Inform your doctor if you are using any of the following medications, as treatment at the same time as this medication should be avoided as much as possible, and a dose adjustment of voriconazole may be necessary:
Inform your doctor if you are taking any of the following medications, as you may need a dose adjustment or monitoring to check that these medications and/or voriconazole are still producing the desired effect:
(used to treat pain and inflammation).
Pregnancy and breastfeeding
Do not use this medication during pregnancy unless your doctor advises you to. Women of childbearing age using this medication should use effective contraceptives. Contact your doctor immediately if you become pregnant during treatment with this medication.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
This medication may cause blurred vision or discomfort due to increased sensitivity to light. If this happens, do not drive or operate tools or machines and inform your doctor.
This medicationcontains sodium
This medication contains 220.8 mg of sodium (main component of table/cooking salt) per vial. This is equivalent to 11% of the maximum recommended daily intake of sodium for an adult.
This medicationcontains cyclodextrin
This medication contains 3,200 mg of cyclodextrin per vial, equivalent to 160 mg/ml when reconstituted in 20 ml. If you have kidney failure, consult your doctor before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will determine the dose based on your weight and the type of infection you have.
Your doctor may change the dose according to your situation.
The recommended dose in adults (including elderly patients) is as follows:
Intravenous route | |
Dose during the first 24 hours (loading dose) | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours (maintenance dose) | 4 mg/kg twice a day |
Depending on your response to treatment, your doctor may decrease the dose to 3 mg/kg twice a day.
Your doctor may decide to reduce the dose if you have mild to moderate cirrhosis.
Use in children and adolescents
The recommended dose in children and adolescents is as follows
Intravenous route | ||
| Children from 2 to less than 12 years of age and adolescents from 12 to 14 years of age who weigh less than 50 kg | Adolescents from 12 to 14 years of age who weigh 50 kg or more; and all adolescents over 14 years | |
Dose during the first 24 hours(loading dose) | 9 mg/kg every 12 hours during the first 24 hours | 6 mg/kg every 12 hours during the first 24 hours |
Dose after the first 24 hours(maintenance dose) | 8 mg/kg twice a day | 4 mg/kg twice a day |
Depending on your response to treatment, your doctor may increase or decrease the daily dose.
This medication must be reconstituted and diluted to the correct concentration by hospital pharmacy or nursing staff (for more information, see the end of this leaflet).
It will be administered by intravenous infusion (in a vein) at a maximum rate of 3 mg/kg per hour for 1 to 3 hours.
If you or your child are taking this medication to prevent fungal infections, your doctor may stop the administration of voriconazole if you or your child experience treatment-related side effects.
If you forget a dose of Voriconazole Sala 200 mg Powder for Solution for Infusion
Given that you will receive this medication under close medical supervision, it is unlikely that you will forget a dose. Nevertheless, inform your doctor or pharmacist if you think you have missed a dose.
If you interrupt treatment with Voriconazole Sala 200 mg Powder for Solution for Infusion
Treatment with this medication should be maintained for as long as your doctor considers it necessary, however, the duration of treatment with this medication should not exceed 6 months.
Patient with compromised immune systems or those with complicated infections may require longer treatments to prevent the infection from coming back. Once your condition improves, intravenous infusion may be replaced by oral tablets.
When your doctor stops treatment with this medication, you should not experience any effects from stopping the treatment.
If you have any further questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. If any appear, it is most likely to be mild and transient. Nevertheless, some may be serious and require medical attention.
Severe Adverse Effects - Stop using this medicine and consult your doctor immediately
Other Adverse Effects
Very frequent: may affect more than 1 in 10 people
Frequent: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
abdominal organs.
potentially life-threatening, which causes painful blisters and ulcers on the skin and mucous membranes, especially in the mouth, skin inflammation, hives, skin redness, and irritation, reddish or purplish skin color that may be caused by low platelet count, eczema.
Rare: may affect up to 1 in 1,000 people
Adverse Effects with Unknown Frequency
Other Important Adverse Effects whose Frequency is Unknown, but which must be Communicated to the Doctor Immediately:
During infusion, there have been infrequent reactions with this medicine (including facial redness, fever, sweating, increased heart rate, and difficulty breathing). The doctor may interrupt the infusion if this occurs.
Since it has been observed that this medicine affects the liver and kidneys, your doctor should monitor liver and kidney function through blood tests. Inform your doctor if you have stomach pain or if the stools have a different consistency.
Cases of skin cancer have been reported in patients treated with this medicine for long periods.
The frequency of sunburn or severe skin reactions after exposure to light or sun was higher in children. If you or your child have skin disorders, your doctor may refer you to a dermatologist who, after consultation, may decide that it is important for you or your child to undergo regular follow-up. Elevated liver enzymes were also observed more frequently in children.
If any of these adverse effects persist or are bothersome, inform your doctor.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the label. The expiration date is the last day of the month indicated.
Once reconstituted, this medicine must be used immediately, although, if necessary, it can be stored for up to 24 hours between 2°C - 8°C (in the refrigerator). This reconstituted medicine must be diluted first with a compatible infusion diluent before being infused. (For more information, see the end of this prospectus).
Medicines should not be thrown away through drains or into the trash. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
Composition of Voriconazol Sala 200 mg Powder for Solution for Infusion
Each vial contains 200 mg of voriconazole, which is equivalent to a concentrated solution of 10 mg/ml once reconstituted following the instructions indicated by the hospital pharmacy or nursing staff (see the information at the end of this prospectus).
Appearance of the Product and Package Contents
This medicine is presented in the form of powder for solution for infusion in single-dose glass vials.
Marketing Authorization Holder and Manufacturer
Laboratorio Reig Jofre, S.A.
Gran Capitán, 10 – 08970
Sant Joan Despí, Barcelona
Spain
Date of the Last Revision of this Prospectus:January 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
--------------------------------------------------------------------------------------------------------------------
This information is intended only for doctors and healthcare professionals:
Information on Reconstitution and Dilution
The required volume of reconstituted concentrate is then added to a compatible infusion solution, including those listed below, to obtain a final solution of this medicine that contains 0.5 to 5 mg/ml of voriconazole.
Required Volumes of Voriconazol Sala 200 mg Concentrate 10 mg/ml
Body Weight (kg) | Volume of Voriconazol Sala Concentrate (10 mg/ml) Required for | ||||
Dose of 3 mg/kg (number of vials) | Dose of 4 mg/kg (number of vials) | Dose of 6 mg/kg (number of vials) | Dose of 8 mg/kg (number of vials) | Dose of 9 mg/kg (number of vials) | |
10 | - | 4.0 ml (1) | - | 8.0 ml (1) | 9.0 ml (1) |
15 | - | 6.0 ml (1) | - | 12.0 ml (1) | 13.5 ml (1) |
20 | - | 8.0 ml (1) | - | 16.0 ml (1) | 18.0 ml (1) |
25 | - | 10.0 ml (1) | - | 20.0 ml (1) | 22.5 ml (2) |
30 | 9.0 ml (1) | 12.0 ml (1) | 18.0 ml (1) | 24.0 ml (2) | 27.0 ml (2) |
35 | 10.5 ml (1) | 14.0 ml (1) | 21.0 ml (2) | 28.0 ml (2) | 31.5 ml (2) |
40 | 12.0 ml (1) | 16.0 ml (1) | 24.0 ml (2) | 32.0 ml (2) | 36.0 ml (2) |
45 | 13.5 ml (1) | 18.0 ml (1) | 27.0 ml (2) | 36.0 ml (2) | 40.5 ml (3) |
50 | 15.0 ml (1) | 20.0 ml (1) | 30.0 ml (2) | 40.0 ml (2) | 45.0 ml (3) |
55 | 16.5 ml (1) | 22.0 ml (2) | 33.0 ml (2) | 44.0 ml (3) | 49.5 ml (3) |
60 | 18.0 ml (1) | 24.0 ml (2) | 36.0 ml (2) | 48.0 ml (3) | 54.0 ml (3) |
65 | 19.5 ml (1) | 26.0 ml (2) | 39.0 ml (2) | 52.0 ml (3) | 58.5 ml (3) |
70 | 21.0 ml (2) | 28.0 ml (2) | 42.0 ml (3) | - | - |
75 | 22.5 ml (2) | 30.0 ml (2) | 45.0 ml (3) | - | - |
80 | 24.0 ml (2) | 32.0 ml (2) | 48.0 ml (3) | - | - |
85 | 25.5 ml (2) | 34.0 ml (2) | 51.0 ml (3) | - | - |
90 | 27.0 ml (2) | 36.0 ml (2) | 54.0 ml (3) | - | - |
95 | 28.5 ml (2) | 38.0 ml (2) | 57.0 ml (3) | - | - |
100 | 30.0 ml (2) | 40.0 ml (2) | 60.0 ml (3) | - | - |
This medicine is a sterile lyophilized product without preservatives for single use. From a microbiological point of view, the solution must be used immediately once reconstituted. If not used immediately, the time and conditions of conservation before use are the responsibility of the user, and it must be kept between 2 and 8°C for a maximum period of 24 hours, unless the reconstitution has been carried out in controlled and validated aseptic conditions.
Compatible Infusion Solutions:
The reconstituted solution can be diluted with:
Sodium chloride 0.9%.
Lactated Ringer's solution at concentrations of 0.5 mg/ml and 5 mg/ml.
5% glucose solutions and lactated Ringer's solution at concentrations of 0.5 mg/ml and 5 mg/ml.
5% glucose solution and 0.45% sodium chloride solution at concentrations of 0.5 mg/ml and 5 mg/ml.
5% glucose solution at concentrations of 0.5 mg/ml and 5 mg/ml.
5% glucose solution with 20 mEq of potassium chloride at concentrations of 0.5 mg/ml and 5 mg/ml.
0.45% sodium chloride solution at concentrations of 0.5 mg/ml and 5 mg/ml.
5% glucose solution and 0.9% sodium chloride solution at concentrations of 0.5 mg/ml and 5 mg/ml.
The compatibility of voriconazole with other diluents different from those specifically mentioned above (or those mentioned below in "Incompatibilities") is unknown.
Incompatibilities:
This medicine should not be infused in the same vein or cannula simultaneously with other drug infusions, including parenteral nutrition (e.g., Aminofusin 10% Plus).
Hemoderivatives should not be infused simultaneously with the administration of this medicine.
Total parenteral nutrition can be administered simultaneously with this medicine, but not in the same vein or cannula.
This medicine should not be diluted with 4.2% sodium bicarbonate solution.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for VORICONAZOL SALA 200 mg POWDER FOR SOLUTION FOR INFUSION – subject to medical assessment and local rules.